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Abstract: Escherichia coli-associated urinary tract infections (UTIs) are among the most 
common bacterial infections in humans. UTIs are usually managed with antibiotic therapy, 
but over the years, antibiotic-resistant strains of uropathogenic E. coli (UPEC) have 
emerged. The formation of biofilms further complicates the treatment of these infections by 
making them resistant to killing by the host immune system as well as by antibiotics. This 
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has encouraged research into therapy using bacteriophages (phages) as a supplement or 
substitute for antibiotics. In this study we characterized 253 UPEC in terms of their 
biofilm-forming capabilities, serotype, and antimicrobial resistance. Three phages were 
then isolated (vB_EcoP_ACG-C91, vB_EcoM_ACG-C40 and vB_EcoS_ACG-M12) 
which were able to lyse 80.5% of a subset (42) of the UPEC strains able to form biofilms. 
Correlation was established between phage sensitivity and specific serotypes of the UPEC 
strains. The phages’ genome sequences were determined and resulted in classification of 
vB_EcoP_ACG-C91 as a SP6likevirus, vB_EcoM_ACG-C40 as a T4likevirus and 
vB_EcoS_ACG-M12 as T1likevirus. We assessed the ability of the three phages to 
eradicate the established biofilm of one of the UPEC strains used in the study. All phages 
significantly reduced the biofilm within 2–12 h of incubation. 
Keywords: UPEC; bacteriophage; biofilms  
 
1. Introduction 
Urinary tract infections (UTIs) are among the most common bacterial infections in humans. They 
account for more than seven million visits to physicians’ offices per year in the United States of 
America [1]. Approximately 20% of women develop UTIs sometime during their lifetime. Above the 
age of 50, men and women have a similar incidence of UTIs [1–5]. UTIs have tremendous economic 
impact on health care systems in both direct and indirect costs associated with treatment [6,7] 
Uropathogenic strains of Escherichia coli (UPECs) account for about 75–85% of UTIs [4,8]. There 
has been an evolution toward antibiotic resistance in UPECs, with decreasing susceptibility to   
first-line agents such as ampicillin, nitrofurantoin, sulphamethoxazole/trimethoprim (SXT) and 
fluoroquinolones [4,9–13]. An alternative to antimicrobial treatment would be of great relevance to 
treat multiresistant UTIs [5], as well as to avoid the continuous selection of resistant pathogens and to 
safeguard the efficacy of antimicrobial agents for cases of emergency and life-threatening infections. 
In hospital-acquired infections as well as in geriatrics patients, most UTI are associated with 
indwelling catheters which act as foci for biofilm formation [14]. Biofilms play a significant role in the 
ability of bacteria to withstand killing by host immune responses and antibiotics. There is a need to 
develop new therapeutic strategies to eradicate biofilm infections [15]. 
The development of biofilms by bacteria does not protect cells from bacteriophage killing. These 
viruses can penetrate the extracellular matrix that binds macromolecules and prevents their diffusion 
into the biofilm [16–18] and kill cells [19–21]. Furthermore, certain phages have evolved to deal with 
capsules by possessing virion-associated polysaccharide depolymerases [22–24] leading us to believe 
that they are ideal agents to help reduce biofilm-associated infections as well as to kill planktonic cells. 
In this paper, we describe a subset of a collection of 253 E. coli isolates from UTIs specifically 
selected on their ability to form biofilms and the activity of three environmentally isolated 
bacteriophages on these strains. To assess their efficacy and safety as therapeutic agents against UPEC, 
the phages were characterized in detail with regards to their spectrum of activity, genetic structure, as 
well as activity on biofilms.  Viruses 2012, 4  473 
 
 
2. Results and Discussion 
2.1. Biofilm Forming Capabilities, Serotype and Antimicrobial Resistance  
Each of the 253 UTI E. coli isolates was screened for static biofilm formation in 96-well untreated 
polystyrene microtiter plates following growth in artificial urine medium as described in the 
Experimental section. Isolates were considered positive for biofilm formation if the crystal violet-stained 
biofilm had an OD600 equal to or greater than 3-fold the value obtained in the well containing bacteria-free 
medium. The UTI E. coli strain CTF073 was used as a positive control and 12 wells of this strain were 
included with each plate of samples of UPEC assayed for biofilm formation. The plotted results were 
the average of three independent experiments, each with six replicates per isolate. Only 42 out of the 
253 E. coli isolates tested in this study produced biofilms in microtiter plate wells with the levels of 
biofilm formation varying among isolates (Figure 1). This is in contrast to a previous study [25] where 
a majority of the UTI strains tested produced biofilms in vitro. A possible reason for the different 
outcomes in the two studies is the fact that UPEC do not form biofilm well on polystyrene plates in 
urine or artificial urine medium as compared to M9 minimal medium used by [25]. Among the 42 
biofilm-forming isolates, Can67 showed the highest level of biofilm formation (OD600 above 1.0) 
whereas MSHS94 and Can72 resulted in weak biofilms formation with an OD600 below 0.2. 
Figure 1. Urinary tract infection (UTI) E. coli isolates positive for biofilm formation on 
96-well microtiter plates. Isolates were considered as biofilm formers if the OD600 for the 
crystal violet-stained biofilm was equal to or greater than 3-fold the OD600 for a bacteria 
free medium. Data points represent an average of three independent experiments, each with 
6 replicate wells for each isolate tested. Isolate CTF073 is a positive control for biofilm 
formation. Error bars indicate standard error of means. 
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The biofilm-forming UTI E. coli isolates totalized 22 different somatic O antigens and 14 different 
H antigens (Table 1). We then investigated their susceptibility profiles against 15 antimicrobials. The 
investigated isolates were frequently resistant with 32 (78%) isolates displaying resistance to 
antimicrobial agents, while 16 (39%) isolates displayed multidrug resistance phenotypes. These results 
are in agreement with previous studies that have shown a high frequency of antimicrobial resistance 
among UPEC [4,9–13]. However, inspection of the different levels of biofilm formation on microtiter 
plates (Figure 1) and comparing this to the results on antimicrobial susceptibility (Table 1) showed that Viruses 2012, 4  474 
 
 
there was no apparent direct correlation between antimicrobial resistance and the amount of biofilm 
formed by each isolate. 
Table 1. List of UTI E. coli forming biofilms, their serotypes, respective antimicrobials 
resistances and sensitivity to the three isolated phages ACG-C91, ACG-C40 and ACG-M12. 
AMC = Amoxicillin/Clavulanic acid; AMP = Ampicillin; FOX = Cefoxitin; TIO = Ceftiofur; 
CRO = Ceftriaxone; CHL = Chloramphinicol; CIP = Ciprofloxacin; KAN = Kanamycin; 
NAL = Nalidixic acid; STR = Streptomycin; SOX = Sulfisoxazole, TCY = Tetracycline; 
SXT = Sulphamethoxazole/Trimethoprim. + symbolises sensitivity to phage; - resistance to 
phage; nd, not determined.  
Strain  Serotype  Antimicrobials to which  
isolates are resistant 
ACG-C40 ACG-C91 ACG-M12 
Can130 O1:NM    +  +  - 
Can18 O2:H4    -  +  - 
CLSC94 O2:H7    +  +  - 
MSHS258 O2:H18    +  +  - 
Can10 O8:H10    -  -  - 
Can128 O8:NM  SOX,  TCY  +  -  - 
MSHS23A  O6:H1  AMP, STR, SOX,  +  -  + 
Can5 O6:H1  NAL  +  -  + 
CLSC82 O6:H1  AMP  +  -  + 
MSHS777 O6:H1  STR  +  -  + 
MSHS58 O6:H25  KAN  -  -  - 
CLSC80 O11:H18  STR,  SOX  +  -  - 
CLSC81 O14:H4    +  -  + 
Can63 O14:H31  TCY  -  -  + 
MSHS94  O18ac:H7  AMP, STR, SOX, TCY  +  +  + 
MSHS343 O18ac:H7    +  +  + 
Can72 O18ac:NM AMP  +  -  - 
CLSC69 O21:H14    -  -  - 
CLSC77A O22:H1    -  -  - 
GMS016A O25:H1    +  +  + 
Can122 O25:H4 
AMP, TIO, CRO, CIP,  
NAL, SOX, TCY, SXT 
- - - 
Can73  O25:H4  AMP, CIP, NAL  -  -  - 
Can67  O25:H4  AMC, AMP, CIP, NAL  -  -  - 
GMS005A O35:H10    +  -  - 
Can23 O68:H18    +  -  - 
Can55  O75:H7  AMC, AMP, FOX, TIO, CRO  +  +  - 
Can93 O75:H7    -  +  - 
Can89 O78:H5    +  -  - 
Can95 O106:H18  CHL,  TCY  -  -  - 
MSHS693A O117:H5    +  -  - 
Can109 O134:H31  NAL  +  +  - 
Can91 O135:H6    +  +  + 
MSHS21 O135:H11    +  -  - Viruses 2012, 4  475 
 
 
Table 1. Cont. 
Strain Serotype 
Antimicrobials to which  
isolates are resistant 
ACG-C40 ACG-C91 ACG-M12 
Can119 O153:H18 
AMP, TIO, CRO, NAL,  
STR, SOX, SXT 
+ +  - 
CLSC14  O153:NM  AMP, STR, SOX, TCY, SXT  +  -  - 
MSHS136 O166:H15  AMC,  AMP  -  -  - 
Can127 OR:H4  AMP,CHL,  TCY  -  +  + 
MSHS885  OR:H4  AMP, CHL, STR, SOX, TCY  +  +  - 
Can108  OR:H4  SOX, TCY, STX  +  +  - 
Can125  OR:H4  AMP, CIP, NAL, SOX, SXT  +  -  + 
Can104 OR:H7    -  +  + 
Can71 OR:H40    +  -  + 
CFT073 nd  nd  +  +  + 
It is important to note that the ability of biofilms to withstand antibiotic killing is a function of their 
mode of growth. Antimicrobial agents have been shown to penetrate biofilms at different rates 
depending on the particular agent and the biofilm [26]. The antimicrobial susceptibility tests carried 
out in this study using the broth microdilution method did not test the susceptibility of the bacteria to 
the antimicrobial agent after biofilm formation. The antimicrobials were added to cell suspensions at 
time of media inoculation and not after the biofilms had formed. The results of [27] demonstrated that 
older biofilms of E. coli resisted ampicillin treatment to a greater extent than their younger 
counterparts. However, in our study, a majority of the biofilm forming E. coli UTI isolates (78%) were 
resistant to at least one antimicrobial agent. This compares to 53.1% of the non-biofilm forming E. coli 
UTI isolates that were resistant to at least one out of the 15 antimicrobials tested (results not shown). 
This is consistent with what is known about antimicrobial resistance among biofilm forming bacterial 
strains [28]. 
2.2. Phage Morphology 
UPEC strains Can 91, Can 40 and MSHS1210 were used as propagating strains for the isolation of 
phages from serially diluted CsCl purified phage concentrate. All three isolates were from midstream 
urine specimens with Can 40 and Can 91 being part of the CANWARD study whereas MSHS1210 
was from the McGill University student health service. The single unique phages isolated from UPEC 
strains Can 91, Can 40 and MSHS1210 were vB_EcoP_ACG-C91, vB_EcoM_ACG-C40 and 
vB_EcoS_ACG-M12, respectively. 
Transmission electron microscopy revealed that phage ACG-C40 has an elongated head, a neck, 
and a contractile tail with tail fibers (Figure 2a). Its head is 110  82 nm, while the extended tail is  
114  8 nm. Phage ACG-M12 (Figure 2b) has an isometric head of about 157 nm in diameter between 
opposite apices and a relatively flexible tail of 172  7 nm, which terminate in 1–2 fibers of 12 nm in 
length. Phage ACG-C91 (Figure 2c) has an isometric head of 65–68 nm and a short tail of 12  8 nm, 
which carries fibers of 13 nm in length with a terminal swelling. Based on their morphology, ACG-C40 
is classified as a member of the family Myoviridae, ACG-M12 is part of the Siphoviridae and ACG-C91 
belongs to the family Podoviridae.  Viruses 2012, 4  476 
 
 
Figure 2. Negative staining of phages ACG-C91 (a); ACG-M12 (b) and ACG-C40   
(c) with 2% uranyl acetate or 2% phosphotungstate. Final magnification is × 297,000. Bars 
indicate 100 nm. 
a b c a a b b c c
  
2.3. Lytic Spectra of Phages against Biofilm Forming UTI Isolates and Relation to Isolates’ Serotypes 
The lytic activity of ACG-C91, ACG-C40 and ACG-M12 tested against the biofilm forming E. coli 
UTI isolates. In the spot tests, 33 (80.5%) of the biofilm forming E. coli UTI isolates were infected by 
at least one of the three phages (Table 1).  
Out of the three phages isolated in this study, phage ACG-C40 had the broadest host range, with the 
ability to lyse 28 (66.67%) of the biofilm forming UTI E. coli isolates tested (Table 1). It is not 
unusual for phages in the family Myoviridae to have such a large host range. A previous study by [29], 
showed that bacteriophage T4 lysed 41.1% of the 69 clinical isolates of E. coli tested. Other T4-like 
phages such as AR1 have been observed to have similar broad host ranges [30]. The ability of phage 
ACG-C40 to cause lysis in a wide range of E. coli isolates with different serotypes makes it an 
important candidate for phage therapy applications. The broad host range of UTI E. coli isolates is an 
indicator of how well adapted phage ACG-C40 is to infecting UPEC, which in itself is a desirable 
property for a phage to be used in phage therapy against such strains. The criteria of choosing phages 
which are well adapted for infection of targeted hosts for therapeutic purposes have been applied in 
similar previous studies [31–33].  
The correlation between host serotype and phage sensitivity is seen in the fact that among the 
biofilm forming strains, all the O25:H4 strains were resistant to the three tested phages. The O6:H1 
strains were sensitive to phages ACG-C40 and ACG-M12. Further in depth studies to identify the 
receptors of the tested phages and the receptors spatial orientation on the surface of the host strains 
under tested conditions would give insight as to why the phages are resistant or susceptible to all 
strains of a given serotype. 
2.4. Salient Bacteriophage Genome Features 
Genome sequencing and bioinformatics analysis of the three isolated phages revealed that all three 
are non-temperate and that none carries any known bacterial virulence genes for humans or animals. Viruses 2012, 4  477 
 
 
None of the three phages possessed a demonstrable extracellular polysaccharide or exopolysaccharide 
(EPS) depolymerase gene. The importance of phage-associated depolymerases in biofilm eradication 
has been recognized in previous studies [22–24,34]. Depolymerase-producing phages were found to be 
more effective in eradicating mature biofilms than non-depolymerase producing phages [34]. Phages 
producing depolymerases have thus been used in concert with antimicrobials to facilitate deeper 
penetration of antimicrobials by degrading the EPS [23,34]. However, phages that do not produce EPS 
depolymerases have also found use in biofilm degradation. Such phages include naturally occurring 
phages such as T4 [16,17,35] and phages such as T7 engineered to express recombinant dispersin B 
(DsbB) [36]. 
2.4.1. Phage ACG-C40 
The sequence of the phage genome consisted of 167,396 bp (G+C content 35%) which is close to 
the genome size of other “T4-like viruses” [37]. It was predicted to encode 282 ORFs and 10 tRNAs. 
The latter clustered between 68, 043 and 68, 989 bp on the phage’s genome.  
The DNA of this virus was resistant to digestion by all restriction endonucleases tested. An analysis 
of the genome of this phage (Additional file: Figure A1; Table A1) reveals that it does, like   
coliphage T4, encode, a glucosyl transferase (orf 060). Bacteriophage T4 contains glucosylated   
5-hydroxymethylcytosine (hmdCyt) instead of cytosine which makes its DNA resistant to most 
restriction enzymes except for EcoRV and NdeI [38]. Based on the presence of the glucosyl   
transferase gene and the resistance to enzymes, we conclude that bacteriophage ACG-C40 also 
contains hypermodified bases, probably glucosylated hmdCyt. 
The genome of this phage revealed that the phage potentially encodes two versions of the Hoc 
protein; a shorter and a longer version which may result from translational frameshifting generating 
Hoc protein with C termini of different lengths (supplementary file: Table S1).  
2.4.2. Phage ACG-C91 
Phage ACG-C91 has a 43,731 bp genome with G+C content of 45% and predicted 55 ORFs 
(supplementary file: Table S2). The phage DNA was sensitive to restriction enzymes BglI, XbaI, 
EcoRV, EcoRI, NdeI and SalI. 
2.4.3. Phage ACG-M12 
Phage ACG-M12 has a 46, 054 bp genome with a G+C content of 44% and 77 ORFs 
(supplementary file: Table S3). The phage DNA was sensitive to all restriction enzymes tested except 
NaeI and SmaI. 
2.5. Comparative Genomics  
Pairwise comparisons using CoreGenes 3.0 [39] at default stringency setting (“75”) revealed that at 
the protein level, ACG-C40, ACG-C91 and ACG_M12 were 85.9% ,78.8% and 77.3% similar to 
bacteriophages T4, SP6 and RTP, respectively. Bacteriophage ACG-C40 genome encodes 239 proteins 
homologous to T4 proteins, ACG-C91 genome has 41 encoded proteins homologous to those of SP6 Viruses 2012, 4  478 
 
 
and ACG-M12 genome encodes 58 proteins with homology to RTP proteins (supplementary files: 
Table A1; Table A2; Table A3). 
A Mauve alignment [40,41] of phage ACG-C91 DNA against the genome of phage SP6 shows 
regions of sequence similarity (coloured red) with two regions where there are no DNA sequence 
similarities (coloured white). The regions of non-sequence similarity correspond to the regions 
encoding phage ACG-C91 internal virion protein proteins (orf 38), putative tail protein (orf 41) and the 
endosialidase (orf 53). The genome region encoding the endosialidase is lacking altogether in phage 
SP6 (supplimentary file: Table A1; supplementary file: Figure A2a). This protein is found in K1-specific 
phages, such as K1F
  and K1-5, that encode virion-associated endosialidases hydrolyzing the K1 
polysialic acid structure of the K1 capsule-producing E.coli strains. Mauve alignment of ACG-M12 
against the genome of phage RTP was also performed and it revealed regions of sequence similarity 
(red) interspersed with four regions where no sequence similarity exists (white). The regions of 
genome homology disparity include phage ACG-M12 genome regions encoding: hypothetical proteins 
orf2, orf3 and orf4 (1025 bp–1588 bp), the major tail protein orf26 (12435 bp–13091 bp), putative tail 
fibre orf47 (29255–32074) and conserved hypothetical proteins orf62 and orf63 (supplementary file: 
Figure A2 b). 
2.5. Bacteriophage Eradication of Established Biofilms  
UTI E. coli isolate Can 91 was selected to determine the effectiveness of the isolated phages to 
degrade established biofilms because of the isolate’s ability to form strong biofilms in microtiter wells 
(OD600 0.538) after 48 hrs and its sensitivity to all the three phages isolated. Phages ACG-C40, ACG-C91 
and ACG-M12 treatment of preformed UTI E. coli Can 91 biofilms yielded reductions (based on 
OD600 measurement of CV-stained cells) in biofilm mass compared to untreated controls (Figure 3). 
All of the three phages displayed, at low concentrations (10
5 PFU/mL), a steady reduction of biofilm 
biomass over time with the largest percentage reduction of biofilm biomass being realized after 8 h 
incubation. The same pattern was also observed at higher phage concentrations (10
7 PFU/mL and  
10
9 PFU/mL). At all phage concentrations, it was evident that the biofilm started re-establishing itself 
after 24 h (Figure 3). 
These results indicate that under the conditions tested, the biofilm reduction by the phages is not 
dose-dependent, a fact that could be taken advantage of if the phages are to be applied in vivo to 
remove established biofilms. It would mean that low titers of the phages were as effective as using a 
higher titer in eradicating established biofilms. Re-establishment of biofilms after 24 h exposure to the 
phages in vitro may be attributed to development of bacterial resistance against the phages. This could 
be overcome by using a cocktail of phages. It may also be a good strategy to augment phage treatment 
with chemical antimicrobials which will be effective in prevention of the re-establishment of biofilms 
by the phage resistant cells. 
Further studies need to be carried out to assess the efficacy of phage ACG-C40, ACG-C91 and 
ACG-M12 in the prevention of biofilm formation for comparison with this study where we have 
assayed their efficacy in the eradication of established biofilms.  Viruses 2012, 4  479 
 
 
Figure 3. Phage disruption of established E. coli strain Can 91 biofilm. Biofilms grown in 
polystyrene microtiter plate wells for 48 h, were initially inoculated with 10
5, 10
7 and 10
9 pfu 
of phages (a) ACG-C40 and (b) ACG-C91 (c) ACG-M12. After 2, 4, 8 and 24 h of phage 
treatment at 37 °C, average biofilm biomass in corresponding microtiter plate wells, were 
scored relatively to untreated control samples (100%) and represented on the Y-axes. Three 
independent experiments were performed, each starting from a different overnight culture 
and each with six repeats for each parameter combination. Error bars indicate standard 
error of means.  
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3. Experimental Section 
3.1. Sampling and E. coli Strain Isolation  
A group of 123 strains of UTI E. coli were isolated from women with community-acquired UTI 
either from a student health service (McGill University, Montréal, QC, Canada) or at a community 
health center also in Montréal. To ensure no bias in the selection of isolates due to recurrent UTI or 
treatment failures, only one isolate per patient was used.  
An additional 130 isolates were part of the ongoing Canadian national surveillance study 
(CANWARD) for testing urinary culture pathogens for antimicrobial susceptibilities. The study 
involved out-patients attending hospital clinics and emergency rooms, and in patients on medical and 
surgical wards, and in intensive care units [42]. Each study site was asked to submit only clinically 
significant isolates, as defined by local site criteria, from out- and in-patients with urinary infections. 
Fifty (2009) to 100 (2007, 2008) consecutive urinary tract isolates per year per medical center site (one 
isolate per patient) were collected. Primary isolate identification was performed by the submitting 
medical center site and confirmed by the coordinating laboratory, as required, based on morphological 
characteristics and spot tests [43]. If an isolate identification made by the coordinating laboratory did 
not match that provided by the submitting site, the isolate was removed from the study. All isolates 
were stored at −70 °C in skim milk.  
At the Department of Epidemiology, Biostatistics and Occupational Health of McGill University, 
the isolates from the McGill University student health service and the community health center, also in 
Montréal, as well as those from the CANWARD study were recovered on MacConkey and CLED agar 
(Uricult dipslides: Orion Diagnostica, Oy, Finland). A single representative colony was picked from 
the MacConkey side of the Uricult slide and grown in LB broth and archived in 15% glycerol at  
−80 °C. When needed, further testing, based upon indole production and the presence of lysine or 
ornithine decarboxylase, was also performed to confirm the bacterial identification.  
3.2. Culture Conditions  
For all experiments, bacteria were grown in LB medium or synthetic urine medium. The latter 
medium was based on that devised by [44], and its composition and method of sterilization have been 
described previously [45]. Briefly the medium was composed of CaCl2, 0.65 g/L; MgCl2, 0.65 g/L; 
NaCl, 4.6 g/L; Na2SO4, 2.3 g/L; Na3-citrate, 0.65 g/L; Na2-oxalate, 0.02 g/L; KH2PO4, 2.8 g/L; KCl, 
1.6 g/L; NH4Cl, 1.0 g/L; urea, 25 g/L; creatinine, 1.1 g/L; Luria-Bertani (LB) broth (Difco, Sparks, 
MD, USA), 10 g/L. The pH of the medium is adjusted to pH 5.8 prior to sterilization by filtration 
through a 0.2-µm filter. 
3.3. E. coli Serotyping  
Identification of somatic (O) and flagellar (H) antigens was performed by standard agglutination 
methods [46]. The isolates were serotyped at the Public Health Agency of Canada, Laboratory for 
Foodborne Zoonoses, Guelph, ON, Canada. Viruses 2012, 4  481 
 
 
3.4. Susceptibility Testing  
The broth microdilution method was used (Sensititre System; Trek Diagnostics, Cleveland, OH), 
following the protocols of the Canadian Integrated Program for Antimicrobial Resistance   
Surveillance [47,48]. Each E. coli isolate was tested for the following antimicrobial agents 
(breakpoints are indicated in parentheses): amikacin (≥64  μg/mL), amoxicillin-clavulanic acid   
(≥32 and ≥16 µg/mL, respectively), ampicillin (≥32 µg/mL), cefoxitin (≥32 µg/mL), ceftiofur (≥8 μg/mL), 
ceftriaxone (≥2 µg/mL) (11), chloramphenicol (≥32 µg/mL), ciprofloxacin (≥4 µg/mL), gentamicin 
(≥16  μg/mL), kanamycin (≥64  μg/mL), naladixic acid (≥32  μg/mL), streptomycin (≥64  μg/mL), 
sulfisoxazole (≥512  μg/mL), tetracycline (≥16  μg/mL), and trimethoprim-sulfamethoxazole   
(≥4 and ≥76 μg/mL, respectively). 
3.5. Bacteriophage Isolation  
Three liters of preliminary treated sewage sample from the Guelph water treatment plant were 
centrifuged at 3,000 RPM for 20 min to eliminate solid debris. The clarified supernatant was 
concentrated to 400 mL using the tangential flow system as described in [49]. NaCl (20.5 g) was then 
added to the concentrate and stirred until it dissolved before 40 g of polyethylene glycol was added to 
precipitate the phage present in the concentrate. This was left overnight while being stirred gently with 
a magnetic stirrer at 4 C. Precipitated phage was recovered by centrifugation at 3,000 RPM for 10 min 
and resuspended in 3 mL SM buffer [50]. This was subjected to two rounds of CsCl gradient 
purification steps and the resulting viral band isolated. 
E. coli isolates Can 91, Can 40 and MSHS1210 were used as propagating strains for the isolation of 
single plaques from serially diluted CsCl purified phage concentrate. All three isolates were from 
midstream urine specimens with Can 40 and Can 91 being part of the CANWARD study whereas 
MSHS1210 was from the McGill University student health service.  
LB agar (Difco) plugs from standard agar overlay method [51] were resuspended in 500 µL SM 
buffer, diluted and used for further single plaque isolation on the respective E. coli propagation strains. 
This was repeated three times for each strain to ensure unique phages for each UPEC isolate. The 
single unique phages isolated from E. coli isolates Can 91, Can 40 and MSHS1210 were named 
vB_EcoP_ACG-C91, vB_EcoM_ACG-C40 and vB_EcoS_ACG-M12, respectively, following the 
naming convention of [52]. 
3.6. Transmission Electron Microscopy  
Phages were pelleted at 25,000 × g for 1 hour, using a Beckman high-speed centrifuge and a   
JA-18.1 fixed-angle rotor (Beckman, Palo Alto, CA, USA). Phage pellets were washed twice under the 
same conditions in neutral 0.1 M ammonium acetate and resuspended. The phages were then deposited 
on copper grids with carbon-coated Formvar films and stained with 2% uranyl acetate (pH 4) or 2% 
phosphotungstate (pH 7.2). They were examined in a Philips EM electron microscope. Magnification 
was calibrated using T4 phage tails as size standards. Viruses 2012, 4  482 
 
 
3.7. Bacteriophage DNA Isolation, Restriction Analysis and Sequencing  
To separate phage from bacterial debris, crude phage lysates were centrifuged at 10, 000 × g for 15 min 
at 4 °C. Bacterial nucleic acids in the supernatants were digested with pancreatic DNase 1 and RNase A, 
each to a final concentration of 10 μg/mL (Sigma-Aldrich Canada Ltd., Oakville, ON, USA). Phage 
particles were then precipitated in the presence of 10% w/v (final concentration) polyethylene glycol 
(PEG-8000; Sigma-Aldrich) at 4 °C overnight. The precipitated phage particles were recovered by 
centrifugation, resuspended in TM buffer (10 mM Tris-HCl, pH 7.8, 1 mM MgSO4). The DNA was 
extracted from a portion of the precipitated viral particles using the SDS/proteinase K method 
modified from [50], followed by extraction with phenol:chloroform:isoamyl alcohol (25:24:1, vol/vol), 
ethanol precipitation and resolution in 10 mM Tris-HCl (pH 7.5). The DNA was characterized 
spectrophotometrically. 
Phage DNA was digested with restriction enzymes BamHI, BglI, EcoRV, HindIII, NaeI, XbaI, 
NdeI, PstI, and SmaI (New England Biolabs, Hertfordshire, UK), according to the manufacturer's 
instructions. Phage Lambda DNA (Fermentas Inc., Hanover, MD, USA) digested by the same enzymes 
was used as a positive control for the restriction digest analysis. 
The DNA was subjected to pyrosequencing (454 technology) at the McGill University and Génome 
Québec Innovation Centre (Montréal, QC, Canada) to between 195 and 930 fold coverage. 
3.8. Bioinformatic Analysis  
The sequences were rearranged to resemble their GenBank homologs and annotated using 
MyRAST [53]. The generated gbk file was incorporated into Kodon (Applied Maths, Austin, TX, 
USA) and proof-read. Proteins were generated using gbk2faa program [54] and screened for homologs 
using BLAST algorithm [55]. In addition they were searched for conserved motifs in the Pfam 
database [56] and transmembrane helix predictions using TMHMM [57] and Phobius [58]. The 
sequence was also screened for tRNAs using tRNAscan-SE program [59]. The final sequences were 
converted to Sequin format [60] using gbk2sqn [61] before deposition into GenBank. The accession 
numbers are ACG-C91 JN986844, ACG-M12 JN986845 and ACG-C40 JN986846. 
3.9. Biofilm Assay  
Each of the 253 E. coli isolates was screened for biofilm formation using the 96-well plate assay as 
described in [62], with minor modifications. Briefly, E. coli isolates were used to inoculate 5 mL of 
synthetic urine medium and grown for 16 h at 37 C. A 1:100 dilution of each of the cultures was made 
in synthetic urine media and 200 µL of each diluted culture was added to six wells in an untreated  
96-well polystyrene flat-bottomed, 96-well microtiter plates (Costar; Corning Inc., Corning, NY, 
USA). The plate was covered and incubated 37 C for 48 h without agitation. Negative control wells 
that contained 200 µL of sterile synthetic urine media only were included. Following incubation, 
planktonic bacteria were removed by pipetting out the culture and washing the wells twice with PBS to 
remove loosely bound cells, using a multichannel pipettor. A 1% (wt/vol; 210 µL) crystal violet (CV) 
solution was added to the wells for 10 min. The CV stain was then decanted and the unbound stain 
removed by washing the plate in a water tray. The plates were left to dry following which 200 µL of Viruses 2012, 4  483 
 
 
95% ethanol added in each well to solubilize the bound CV from the stained E. coli biofilms. The 
absorbance
 of CV at 600 nm was measured in a Wallac-Victor
2 1420 Multilabel
 Counter (Perkin-Elmer, 
Boston, MA, USA). 
3.10. Bacteriophage Host Range on Biofilm Forming UPEC Isolates  
The host range of phages ACG-C91, ACG-C40 and ACG-M12 against biofilm forming E. coli UTI 
isolates was determined by standard spot tests [63]. Briefly, this involved mixing 200 µL overnight 
culture of each isolate with 3 mL molten top LB agar (0.6% agar) and pouring on 96 mm diameter 
plates containing bottom agar. This was left to solidify then 10 l of phage to be tested was spotted in 
the middle of the plate and left to dry before incubation inverted overnight at 37 C. 
3.11. Bacteriophage Activity against Established Biofilms  
E. coli isolate CLSC 94 was used to test the effect of the two environmentally isolated phages 
ACG-C40 and ACG-C91 on established biofilms. The method of [64] with minor modifications was 
used. Briefly, stationery-phase culture of E. coli CLSC94 was diluted 1:100 and 200 µL of the 
inoculum added to 12 wells of an untreated 96-well polystyrene microtiter plate. This was incubated 
for 24 h at 37 C without agitation. Negative control wells that contained 200 µL of sterile synthetic 
urine media only were included. Following incubation period, planktonic bacteria were removed by 
pipetting out the culture, and washing the wells twice with PBS to remove loosely bound cells. The 
wells were then treated with 200 µL of ACG-C40 and ACG-C91 phage lysate at titers of 10
5, 10
7 and 
10
9 PFU/mL added to each of the 12 wells. Phages were also added to the negative control wells which 
contained only UPEC cells grown in sterile synthetic urine media. After incubation periods of 2 h, 4 h, 
8 h and 24 h, planktonic bacteria were removed and wells were washed twice with PBS to remove 
loosely bound cells. The remaining biofilm was stained as described above.  
4. Conclusions  
We were able to isolate phages that are effective against UPECstrains and are able to degrade 
biofilms formed by the UPEC strains. The phages’ DNA sequences were determined. They were 
screened and found to be devoid of undesirable laterally transferable virulence and antimicrobial 
resistance determinants on the basis of homologies with known virulence and resistant genes available 
in GenBank. 
The study resulted in detailed characterization of a large set of UPEC with regards to biofilm 
forming capabilities and antimicrobial resistance. The candidate phages with adequate lytic spectrum 
for therapeutic purposes (including efficacy for disruption of existing biofilms) were characterized in 
detail. The phages have a promising potential for phage therapy of UTIs caused by biofilm forming UPEC. 
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